${\tt TABEL}.\ Overzicht\ van$ $de\ prevalentie\ van$ neurologische $en\ psychiatrische\ klachten$ $in\ een\ cohort\ van$ 236379 ex-Covid-19patiënten in de VS.[3]

	All patients	Patients without hospitalisation	Patients with hospitalisation	Patients with ITU admission	Patients with encephalopathy
Intracranial haemorrhage (any)	0·56% (0·50–0·63)	0·31% (0·25–0·39)	1·31% (1·14–1·52)	2·66% (2·24–3·16)	3·61% (2·97-4·39)
Intracranial haemorrhage (first)	0·28% (0·23–0·33)	0·14% (0·10–0·20)	0.63% (0.50–0.80)	1·05% (0·79–1·40)	1·19% (0·82–1·70)
Ischaemic	2·10%	1·33%	4·38%	6·92%	9·35%
stroke (any)	(1·97–2·23)	(1·22–1·46)	(4·05–4·74)	(6·17–7·76)	(8·23–10·62)
Ischaemic	0·76%	0·43%	1·60%	2·82%	3·28%
stroke (first)	(0·68–0·85)	(0·36–0·52)	(1·37–1·86)	(2·29–3·47)	(2·51–4·27)
Parkinsonism	0·11%	0·07%	0·20%	0·26%	0·46%
	(0·08–0·14)	(0·05–0·12)	(0·15–0·28)	(0·15–0·45)	(0·28–0·78)
Guillain-Barré	0·08%	0·05%	0·22%	0·33%	0·48%
syndrome	(0·06–0·11)	(0·03–0·07)	(0·15–0·32)	(0·21–0·54)	(0·20–1·14)
Nerve, nerve root, or plexus disorders	2·85% (2·69–3·03)	2·69% (2·51–2·89)	3·35% (3·02–3·72)	4·24% (3·58–5·03)	4·69% (3·81–5·77)
Myoneural junction or muscle disease	0·45% (0·40–0·52)	0·16% (0·12–0·20)	1·24% (1·05–1·46)	3·35% (2·76–4·05)	3·27% (2·54–4·21)
Encephalitis	0·10%	0·05%	0·24%	0·35%	0·64%
	(0·08–0·13)	(0·03–0·08)	(0·17–0·33)	(0·19–0·64)	(0·39–1·07)
Dementia	0·67%	0·35%	1·46%	1·74%	4·72%
	(0·59–0·75)	(0·29–0·43)	(1·26–1·71)	(1·31–2·30)	(3·80–5·85)
Mood, anxiety, or psychotic disorder (any)	23·98% (23·58–24·38)	23·59% (23·12–24·07)	24·50% (23·76–25·26)	27·78% (26·33–29·29)	36·25% (34·16–38·43)
Mood, anxiety, or psychotic disorder (first)	8·63% (8·28–8·98)	8·15% (7·75–8·57)	8·85% (8·22–9·52)	12·68% (11·28–14·24)	12·96% (11·13–15·07)
Mood disorder	13·66%	13·10%	14·69%	15·43%	22·52%
(any)	(13·35–13·99)	(12·73–13·47)	(14·09–15·32)	(14·27–16·68)	(20·71–24·47)
Mood disorder	4·22%	3·86%	4·49%	5·82%	8·07%
(first)	(3·99–4·47)	(3·60-4·14)	(4·05–4·99)	(4·86–6·97)	(6·56–9·90)
Anxiety	17·39%	17·51%	16·40%	19·15%	22·43%
disorder (any)	(17·04–17·74)	(17·09–17·93)	(15·76–17·06)	(17·90–20·48)	(20·65–24·34)
Anxiety	7·11%	6·81%	6·91%	9·79%	9·24%
disorder (first)	(6·82–7·41)	(6·47–7·16)	(6·38–7·47)	(8·65–11·06)	(7·70–11·07)
Psychotic	1·40%	0·93%	2·89%	2·77%	7·00%
disorder (any)	(1·30–1·51)	(0·83–1·04)	(2·62–3·18)	(2·31–3·33)	(6·01–8·14)
Psychotic	0·42%	0·25%	0·89%	0·70%	2·12%
disorder (first)	(0·36–0·49)	(0·19–0·33)	(0·72–1·09)	(0·46–1·06)	(1·53–2·94)
Substance use disorder (any)	6·58%	5·87%	8·56%	10·14%	11·85%
	(6·36–6·80)	(5·63–6·13)	(8·10–9·04)	(9·25–11·10)	(10·55–13·31)
Substance use disorder (first)	1·92%	1·74%	2·09%	3·15%	2·58%
	(1·77–2·07)	(1·58–1·91)	(1·82–2·40)	(2·60–3·82)	(1·91–3·47)
Insomnia (any)	5·42%	5·16%	5·95%	7·50%	9·82%
	(5·20–5·64)	(4·91–5·42)	(5·53–6·39)	(6·66–8·44)	(8·57–11·24)
Insomnia (first)	2·53%	2·23%	3·14%	4·24%	5·05%
	(2·37–2·71)	(2·05–2·43)	(2·81–3·51)	(3·55–5·07)	(4·10–6·20)
Any outcome	33·62%	31·74%	38·73%	46·42%	62·34%
	(33·17–34·07)	(31·22–32·27)	(37·87–39·60)	(44·78–48·09)	(60·14–64·55)
Any first outcome	12·84%	11·51%	15·29%	25·79%	31·13%
	(12·36–13·33)	(10·98–12·07)	(14·32–16·33)	(23·50–28·25)	(27·29–35·36)

Data are percentage at 6 months (95% CI). Additional outcomes are presented in the appendix (pp 27–28).

ITU=intensive therapy unit.